• The Journal of Internal Korean Medicine
• /
• v.39 no.4
• /
• pp.592-604
• /
• 2018

Objectives: This study is to review the effect of Korean medicinal herbs on treatment of benign prostatic hyperplasia induced in rat models, as reported in domestic and foreign journals. Methods: Six electronic databases (EMBASE, PubMed, Oasis, RISS, CENTRAL, and Koreankt) were searched with terms including benign prostatic hyperplasia to identify study reports on treatment of benign prostatic hyperplasia impairment with Korean medicinal herbs. After selecting several studies, the analysis focused on items reflected in the diagnosis of benign prostatic hyperplasia, such as prostate weight, thickness of the prostate epithelium, and prostate specific antigen. Results: Six studies were reviewed. Testosterone propionate was used as a benign prostatic hyperplasia induction material in all the included studies. Cinnamomum verum (CV), Cynanchum wilfordii (CW), Ponciri fructus (PF), Quisqualis indica (QI), Acorus gramineus (AG), and Melandrium firmum (MF) had reduced prostate weight statistically significantly. The QI gave a better response than finasteride in terms of reducing epithelium thickness, and the response was statistically significant. The prostate specific antigen level was lower in the group treated with CV than in the control group. Conclusions: CV, CW, PF, QI, AG, and MF had distinct therapeutic effects. However it is difficult to determine which of these is better by comparing them numerically because the observation items evaluated in a rat model of benign prostatic hyperplasia.

• The Journal of Internal Korean Medicine
• /
• v.44 no.4
• /
• pp.703-725
• /
• 2023

Objectives: This study investigated Korean medicine doctors' perspectives on clinical practice patterns in the process of developing Korean medicine clinical practice guidelines for benign prostatic hyperplasia. Methods: A questionnaire was developed for Korean medicine doctors. A total of 323 oriental medicine doctors participated in the survey, which was live for a total of 9 days from September 22, 2022, to September 30, 2022. Results: Regarding awareness of treatments for benign prostatic hyperplasia, 63.8% of respondents showed high awareness of Korean medical treatments. However, items such as diagnostic criteria (17.7%), evaluation methods (17.0%), and Western medical treatments (22.9%) showed low recognition rates. In clinical practice, 76.2% of respondents were found to treat five or fewer patients with benign prostatic hyperplasia per month, and the average treatment period was 1 to 3 months for most at 41.2%. Korean medicine doctors diagnosed benign prostatic hyperplasia based on clinical features. The main interventions used were acupuncture, herbal medicine (prescription medicine), and moxibustion. This study has several limitations because of the low response rate for this survey; therefore, the participants are not representative of all Korean medicine doctors. In addition, because the study was conducted broadly on various topics related to benign prostatic hyperplasia, sufficient quality management was not carried out. Further studies that include a larger sample size and more in-depth studies on benign prostatic hyperplasia are needed. Conclusions: It is necessary to develop appropriate and reasonable Korean medicine clinical practice guidelines for benign prostatic hyperplasia.

• Journal of Veterinary Clinics
• /
• v.21 no.2
• /
• pp.200-204
• /
• 2004

A 3-year-old, male Shih-tzu dog with clinical signs of dysuria and hematuria was brought to the Veterinary Teaching Hospital. Chonnam National University. The patient was suspected urolithiasis by history taking and clinical signs but urinary and urethra calculus was not found in the radiographic examination. Enlarged prostatic gland (29.0$\times$28.0 mm) and severe finding of cystitis was observed from the ultrasonographic examination. The dog was finally diagnosed as the secondary urethral obstruction by benign prostatic hyperplasia. Castration was performed to treatment of acute hyperplasia of prostatic gland and prostatic cysts. After 26 days of operation, the prostate was defined small, hypoechoic, symmetric and decreased size (18.5$\times$18.0mm) by ultrasonography and dysuria cured completely.

• The Journal of Internal Korean Medicine
• /
• v.31 no.3
• /
• pp.457-466
• /
• 2010

Objective : In benign prostatic hyperplasia, dihydrotestosterone acts as a potent cellular androgen and promotes prostate growth. Inhibiting enzyme $5{\alpha}$-reductase that is involved in the conversion of testosterone to the active form dihydrotestosterone reduces this excessive prostate growth. The mechanism on benign prostatic hyperplasia is substantiating evidence to support the clinical value in the evaluation of therapeutic efficacy. In this study, we investigated the effects of Lygodium japonicum on cyto-pathological alterations and expression of $5{\alpha}$-reductase in the rat model of benign prostatic hyperplasia induced by castration and testosterone treatment. Methods : Sprague-Dawley rats were treated with testosterone after castration for induction of experimental benign prostatic hyperplasia, which is similar to human benign prostatic hyperplasia in histopathological profiles. Lygodium japonicum as an experimental specimen, and finasteride as a positive control, were administered orally. The prostates were evaluated by histopathological changes and testosterone levels. Also, the prostates were observed by hematological alterations of AST, ALT, ${\gamma}$-GTP, BUN and creatinine. Results : The rats treated with Lygodium japonicum showed a diminished range of luminal cell and duct epithelial cell damage. The stromal elements and connective tissue proliferation of Lygodium japonicum treated group as compared to the control group decreased. Conclusions : These findings suggest that Lygodium japonicum may protect the glandular epithelial cells. We concluded that Lygodium japonicum could be a useful remedy agent for treating the benign prostatic hyperplasia.

• The Journal of Internal Korean Medicine
• /
• v.30 no.2
• /
• pp.327-337
• /
• 2009

Objective : In benign prostatic hyperplasia, dihydrotestosterone acts as a potent cellular androgen and promotes prostate growth. Inhibiting enzyme 5${\alpha}$-reductase, which is involved in the conversion of testosterone to the active form dihydrotestosterone, reduces excessive prostate growth. Recently Scutellaria baicalensis has been related reports about the effect of baicalein on anti-proliferation of the prostate gland. In this study, we investigated the effects of Scutellaria baicalensis on cytopathological alterations and expression of 5${\alpha}$-reductase in the rat model of benign prostatic hyperplasia induced by castration and testosterone treatment. Methods : Sprague-Dawley rat were treated with testosterone after castration for induction of experimental benign prostatic hyperplasia, which is similar to human benign prostatic hyperplasia in histopathological profiles. Scutellaria baicalensis as an experimental specimen, and finasteride as a positive control, were administered orally. The prostates were evaluated by histopathological changes, testosterone levels, and the expression of 5${\alpha}$-reductase genes. Results : While prostates of control rats revealed severe acinar gland atrophy and stromal proliferation, the rats treated with Scutellaria baicalensis showed a diminished range of tissue damage. In the reverse transcription-polymerase chain reaction(RT-PCR) of 5${\alpha}$-reductase genes. Scutellaria baicalensis inhibited the expression of 5${\alpha}$-reductase genes. Conclusions : These findings suggest that Scutellaria baicalensis may protect glandular epithelial cells and also inhibit stromal proliferation in association with the suppression of 5${\alpha}$-reductase. From theses results, we suggest that Scutellaria baicalensis could be a useful remedy agent for treating benign prostatic hyperplasia.

• Journal of Yeungnam Medical Science
• /
• v.26 no.2
• /
• pp.85-92
• /
• 2009

Clinical benign prostatic hyperplasia (BPH) is a multifaceted phenomenon that is due to prostatic and bladder influences as well as nonurological causes. It is also important to differentiate between the more common voiding or obstructive symptoms as well as the more bothersome storage or irritative symptoms. Lower urinary tract symptoms (LUTS) and BPH may be two separate conditions with different underlying pathologies. However, they are often treated incorrectly as one entity. Both conditions are very common and they represent chronic conditions of the aging male. They are often associated with a significant reduction in the patients' quality of life. Although these are not new conditions, there have been enormous changes in the methods of assessing and managing the patients with these conditions. This review describes some of the influential studies in this area and the current trends of the primary treatment for LUTS/BPH.

• The Journal of Internal Korean Medicine
• /
• v.38 no.3
• /
• pp.301-318
• /
• 2017

Objective: The purpose of this study was to develop a standard tool of pattern identification, which will be applied to clinical research, for benign prostatic hyperplasia. Method: The items and structure of the instrument were based on a review of the published literature in China and Korea. The advisory committee on this study included 11 kidney-endocrine professors of the Korean Medical Colleges Division and 4 Korean medicine doctors who had a doctor's degree in the Kidney-Endocrine Division. The advisory committee was questioned regarding pattern identification importance, symptom weight, treatment importance, changes in the symptoms, rare changes in the symptoms, and frequency of prescriptions regarding benign prostatic hyperplasia. Results: The Korean instrument of pattern identification was completed; it was composed of four questions for benign prostatic hyperplasia. Conclusion: We sincerely look forward to improving the instrument through the continuous clinical studies.

• Journal of Animal Reproduction and Biotechnology
• /
• v.37 no.3
• /
• pp.209-212
• /
• 2022

Benign prostatic hyperplasia (BPH) is frequently observed in intact middle-aged or older male dogs with symptoms ranging from asymptomatic to various symptoms such as urination, dyschezia, dysuria, tenesmus, and intermittent serosanguinous or clear serous exudate. A 4-year-old, intact male Welsh corgi with symptoms of intermittent hematuria and serosanguinous exudate at the urethral opening was diagnosed with BPH and intraprostatic hematocyst through ultrasonographic examination and cytology test. The dog was internationally adopted for reproductive purposes and needed to undergo BPH treatment while maintaining fertility. Thus, 2.5 mg finasteride was administered orally once a day for treatment option and therapeutic effects were observed, including loss of clinical symptoms and reduced prostate and intraparenchymal cyst size.

• Nutrition Research and Practice
• /
• v.3 no.4
• /
• pp.323-327
• /
• 2009

This study was to investigate the role of complementary and alternative medicine in the prevention and treatment of benign prostatic hyperplasia. For this purpose, a randomized, double-blind, placebo-controlled trial was performed over 12 months on 47 benign prostatic hyperplasia patients with average age of 53.3 years and international prostate symptom score over 8. Subjects received either sweet potato starch (group A, placebo, 320 mg/day), pumpkin seed oil (group B, 320 mg/day), saw palmetto oil (group C, 320 mg/day) or pumpkin seed oil plus saw palmetto oil (group D, each 320 mg/day). International prostate symptom score, quality of life, serum prostate specific antigen, prostate volume and maximal urinary flow rate were measured. In groups B, C and D, the international prostate symptom score were reduced by 3 months. Quality of life score was improved after 6 months in group D, while those of groups B and C were improved after 3 months, compared to the baseline value. Serum prostate specific antigen was reduced only in group D after 3 months, but no difference was observed in prostate volume in all treatment groups. Maximal urinary flow rate were gradually improved in groups B and C, with statistical significance after 6 months in group B and after 12 months in group C. None of the parameters were significantly improved by combined treatment with pumpkin seed oil and saw palmetto oil. From these results, it is suggested that administrations of pumpkin seed oil and saw palmetto oil are clinically safe and may be effective as complementary and alternative medicine treatments for benign prostatic hyperplasia.

• Korean Journal of Oriental Medicine
• /
• v.16 no.2
• /
• pp.131-141
• /
• 2010

Objective : Benign prostatic hyperplasia(BPH) is one of the most common diseased among elderly men. BPH can be treated with alpha-1 adrenergic blocker or $5{\alpha}$-reductase inhibitor(Finasteride) that reduces serum dihydrotestosterone(DHT). Phellodendri Cortex Ex has been broad studied on its chemical components, pharmacological activity, and clinical effects on anti-inflammation, anti-allergy, anti-tumor, immunity, antibacteria and other bioactivities. In this study, we investigated the therapeutic effects and action mechanism of Phellodendri Cortex Ex with a BPH induced by castration and testosterone treatment. Methods : Sprague-Dawley rats were treated with testosterone after castration for induction of experimental benign prostatic hyperplasia, which is similar to human benign prostatic hyperplasia in histopathological profiles. Phellodendri Cortex as an experimental specimen, and Finasteride as a positive control, were administered orally. The prostates were evaluated by histopathological changes, and the expression of $5{\alpha}$-reductase genes. Results : While prostates of control rats revealed severe acinar gland atrophy and stromal proliferation, the rats treated with Phellodendri Cortex Ex showed a diminished range of the tissue damage. In the reverse transcription-polymerase chain reaction(RT-PCR) of $5{\alpha}$-reductase genes, Phellodendri Cortex inhibited the expression of $5{\alpha}$-reductase genes. Conclusions : These findings suggest that Phellodendri Cortex Ex may protect the glandular epithelial cells and also inhibit stromal proliferation in association with the suppression of $5{\alpha}$-reductase. From these results, we suggest that Phellodendri Cortex Ex could be a useful agent for treating the benign prostatic hyperplasia.